Faster and much more straightforward: getting your clinical trial approved in Brazil
This article was originally published in SRA
Ariye Sidi explains how the approval process for clinical trials in Brazil has improved over the past few years.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.